TipRanks
Advertisement
Advertisement

HK:2595 Stock Latest News

GenFleet Therapeutics Announces Board Composition and Committee Roles
Company AnnouncementsGenFleet Therapeutics Announces Board Composition and Committee Roles
12d ago
2595
GenFleet Therapeutics Announces Resignation of Non-Executive Director
PremiumCompany Announcements
GenFleet Therapeutics Announces Resignation of Non-Executive Director
12d ago
2595
GenFleet to Unveil Key Clinical Data on RAS-Targeted Cancer Drugs
PremiumCompany Announcements
GenFleet to Unveil Key Clinical Data on RAS-Targeted Cancer Drugs
13d ago
2595
GenFleet Reveals GFH375 Combo Added to Proposed Breakthrough Therapy List After Share Price Surge
PremiumCompany Announcements
GenFleet Reveals GFH375 Combo Added to Proposed Breakthrough Therapy List After Share Price Surge
14d ago
2595
GenFleet Advances 2026 H-Share Buyback With Initial Repurchases
PremiumCompany Announcements
GenFleet Advances 2026 H-Share Buyback With Initial Repurchases
15d ago
2595
GenFleet’s KRAS G12D Lung Cancer Drug Shows Strong Phase II Results, Advancing to First Global Phase III Trial
PremiumCompany AnnouncementsGenFleet’s KRAS G12D Lung Cancer Drug Shows Strong Phase II Results, Advancing to First Global Phase III Trial
21d ago
2595
Analyst Initiates Buy on GenFleet, Citing GFH276-Driven Valuation and Emerging Global RAS Franchise
Premium
Ratings
Analyst Initiates Buy on GenFleet, Citing GFH276-Driven Valuation and Emerging Global RAS Franchise
1M ago
GenFleet Advances KRAS G12D Lung Cancer Drug GFH375 into First-Line Phase II Study
Premium
Company Announcements
GenFleet Advances KRAS G12D Lung Cancer Drug GFH375 into First-Line Phase II Study
1M ago
2595
GenFleet Narrows Interim Loss as R&D Spending Climbs and Cash Reserves Remain Strong
PremiumCompany Announcements
GenFleet Narrows Interim Loss as R&D Spending Climbs and Cash Reserves Remain Strong
2M ago
2595
GenFleet Advances First-in-World KRAS Combination Trial in Pancreatic Cancer
PremiumCompany Announcements
GenFleet Advances First-in-World KRAS Combination Trial in Pancreatic Cancer
2M ago
2595
GenFleet Advances Second Phase III Trial for Oral KRAS G12D Lung Cancer Drug
PremiumCompany Announcements
GenFleet Advances Second Phase III Trial for Oral KRAS G12D Lung Cancer Drug
2M ago
2595
GenFleet Therapeutics Schedules Board Meeting to Review Interim Results and Dividend
PremiumCompany Announcements
GenFleet Therapeutics Schedules Board Meeting to Review Interim Results and Dividend
2M ago
2595
GenFleet Therapeutics Raises HK$471.8 Million Through H-Share Placing
PremiumCompany AnnouncementsGenFleet Therapeutics Raises HK$471.8 Million Through H-Share Placing
3M ago
2595
Genfleet Therapeutics Plans HK$471.8 Million H‑Share Placing Under General Mandate
Premium
Company Announcements
Genfleet Therapeutics Plans HK$471.8 Million H‑Share Placing Under General Mandate
3M ago
2595
GenFleet Therapeutics to Launch HK$350 Million H-Share Buyback
Premium
Company Announcements
GenFleet Therapeutics to Launch HK$350 Million H-Share Buyback
3M ago
2595
GenFleet’s KRAS G12D Inhibitor Shows Early Efficacy in Cholangiocarcinoma and Colorectal Cancer
PremiumCompany Announcements
GenFleet’s KRAS G12D Inhibitor Shows Early Efficacy in Cholangiocarcinoma and Colorectal Cancer
4M ago
2595
GenFleet’s First-in-Class Cachexia Antibody Shows Promising Phase I Data at ASCO
PremiumCompany Announcements
GenFleet’s First-in-Class Cachexia Antibody Shows Promising Phase I Data at ASCO
4M ago
2595
GenFleet Shareholders Back All Resolutions at 2026 Annual General Meeting
PremiumCompany Announcements
GenFleet Shareholders Back All Resolutions at 2026 Annual General Meeting
5M ago
2595
GenFleet Asserts Independent IP for Pan RAS Inhibitor GFH276 Amid Sector Dispute
PremiumCompany Announcements
GenFleet Asserts Independent IP for Pan RAS Inhibitor GFH276 Amid Sector Dispute
5M ago
2595
GenFleet Therapeutics Sets 2025 AGM to Seek Mandates on Governance and Share Capital
PremiumCompany AnnouncementsGenFleet Therapeutics Sets 2025 AGM to Seek Mandates on Governance and Share Capital
6M ago
2595
GenFleet’s KRAS G12D Drug Wins Second Breakthrough Tag as First Pancreatic Cancer Monotherapy in China
Premium
Company Announcements
GenFleet’s KRAS G12D Drug Wins Second Breakthrough Tag as First Pancreatic Cancer Monotherapy in China
6M ago
2595
GenFleet Tightens Audit Committee Charter to Bolster Governance
Premium
Company Announcements
GenFleet Tightens Audit Committee Charter to Bolster Governance
7M ago
2595

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >